Mizuho cuts Haemonetics price target to $70, keeps Outperform rating

Mizuho Securities analysts lowered their price target for Haemonetics Corp. (NYSE: HAE) to $70^[1] while maintaining an Outperform rating.

The change matters because Haemonetics is a key player in the blood‑management market; a lower target can pressure the stock and influence investor sentiment across the U.S. healthcare sector—especially as investors compare it to peers.

Mizuho’s note cites a previous target of $80^[1], but InsiderMonkey reported the firm had been aiming for $90^[2] before the cut, indicating a range of prior expectations. The reduction reflects the firm’s reassessment of growth prospects after recent earnings.

The timing of the adjustment also varies. Yahoo Finance recorded the price‑target change on April 13^[1] (year not specified), whereas InsiderMonkey placed it on August 14, 2025^[2], suggesting the revision may have been communicated in stages.

Adding context, an MSN report notes that the average one‑year price target for Haemonetics among analysts sits at $86^[3]. That consensus figure is higher than Mizuho’s $70 target, underscoring a divergence in outlook.

Mizuho’s decision follows Haemonetics’ fiscal first‑quarter 2025 results, which fell short of internal forecasts and prompted a sector‑wide review by Yahoo Finance^[1]. The earnings miss highlighted slower demand for the company’s blood‑collection devices, a factor that likely contributed to the lower target.

Despite the cut, Mizuho kept its Outperform recommendation, signaling confidence that the company can rebound. The firm expects the new target to serve as a baseline while it monitors product rollout and cost‑control measures.

**What this means** – The $70 target sets a lower floor for Haemonetics’ valuation, potentially nudging the stock down in the near term. However, the broader analyst consensus of $86 suggests that many investors still see upside if the company can address its Q1 shortfall and capture growth in the medical‑device market.